SecBot SecBot
8-K ·Filed May 5, 2026

SYRE

Spyre Therapeutics, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001636282-26-000051
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The wider net loss and cash burn of $57.4M in operating cash flow are offset by the $1.18B pro forma cash position and positive pipeline catalysts. Key catalysts to watch: SPY002 and SPY003 topline data in mid-2026 and Q3 2026, RA sub-study readout in Q3 2026, and combination data in 2027. The $463M offering closed in April 2026 removes near-term dilution risk but the stock may trade on pipeline data rather than financials.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$71.01
T+0 close · May 5, 2026 · via day close
Latest settled
+42.94%
T+60 · $101.50
Vs SPY
+40.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $71.01entry
  2. T+1 · 7mo ago +2.80%α +1.42% · $73.00
  3. T+5 · 6mo ago +7.63%α +5.65% · $76.43
  4. T+20 · 6mo ago −2.61%α −7.56% · $69.16
  5. T+60 · 4mo ago +42.94%α +40.20% · $101.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spyre Therapeutics reported Q1 2026 financial results with a net loss of $69.0M ($0.74 per share), wider than the $44.8M loss in Q1 2025, driven by higher R&D and G&A expenses and a $30.4M non-cash charge from CVR fair value changes. The company highlighted positive Phase 2 data for SPY001 in ulcerative colitis, over-enrollment of the RA sub-study, and a pro forma cash position of $1.18B following a $463M public offering, providing runway into H2 2029. The wider loss and lack of revenue (pre-revenue biotech) make this a neutral-to-bearish financial report, but the strong pipeline progress and extended cash runway are positive offsets.

Key Financial Metrics

EPS
−$0.74
est −$0.66 · -12.1%
Rating
in line

Key Facts

  • Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025, driven by higher R&D ($60.4M vs $41.6M) and G&A ($15.2M vs $11.9M) expenses
  • Pro forma cash of $1.18B as of March 31, 2026, including $435.3M net proceeds from April 2026 public offering, providing runway into H2 2029
  • Positive topline Phase 2 data for SPY001 in ulcerative colitis: 40% clinical remission, 51% endoscopic improvement, statistically significant RHI reduction
  • RA sub-study of SKYWAY Phase 2 trial over-enrolled, topline readout accelerated to Q3 2026
  • Net cash used in operating activities was $57.4M for Q1 2026
  • Recognized $30.0M gain on sale of legacy Aeglea asset pegzilarginase upon FDA approval
  • CVR liability increased to $56.95M from $26.68M at year-end 2025, driving $30.4M other expense

Financial Impact

Net loss widened by $24.2M YoY to $69.0M; no revenue reported (pre-revenue biotech)

net losscash positionR&D expensesoperating cash flow

Risk Factors

  • Widening net loss and increasing R&D spend ($60.4M in Q1) could pressure cash runway if pipeline milestones are delayed
  • CVR liability of $56.95M creates potential future cash outflow of ~$23M in Q2 2026
  • Clinical-stage biotech with no approved products or revenue, all value depends on clinical trial outcomes
  • Recent $463M offering dilutes existing shareholders; 78.8M shares outstanding vs 60.3M a year ago

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001636282-26-000051
Document: syre-20260505.htm0001636282-26-000051
Document: 0001636282-26-000051-index-headers.html0001636282-26-000051
Document: 0001636282-26-000051-index.html0001636282-26-000051
Document: 0001636282-26-000051.txt0001636282-26-000051
8-K Data (Synthetic)0001636282-26-000051

Track record

36 reports on SYRE

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  2. Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
  3. Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  4. Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
  5. Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  6. Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
  7. Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  8. Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  9. Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
  10. Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
Showing 10 of 36

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026